Joshua D Brody

19PUBLICATIONS
182CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMedical devicesAllergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Aug 20, 2026
Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial.

|Aug 05, 2026
First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma.

|Jul 16, 2026
Dendritic cells control tertiary lymphoid structure development and maintenance in cancer.

|Apr 29, 2026
mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression.

|Jul 15, 2025
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.

Taylor R Brooks, Emily C Zabor, Yohanna B Bedelu

|Jun 11, 2025
Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas.

Kevin J Harrington, Stephane Champiat, Joshua D Brody

Pageof 4

Frequent Collaborators

5 joint publications

Yasmin H Karimi

4 joint publications

Brian D Brown

4 joint publications

Miriam Merad

3 joint publications

Lorenzo Falchi